Previous 10 | Next 10 |
2024-02-12 15:06:51 ET More on CymaBay, Gilead, etc. Gilead Sciences: Cheap For A Reason Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript Gilead Sciences, Inc. 2023 Q4 - Results - Earnings Call Presentation Gilead to acquire CymaBay for $32.50/sh...
2023-11-21 16:36:04 ET More on Inventiva Inventiva S.A. (IVA) Q2 2023 Earnings Analyst Call Transcript Inventiva and Hepalys Pharma to develop and commercialize Lanifibranor in Japan and South Korea Inventiva announced €35.7M funding, eyes future raise to meet...
2023-10-27 15:00:00 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
2023-09-29 14:58:08 ET Inventiva S.A. (IVA) Q2 2023 Earnings Analyst Conference Call September 29, 2023, 08:00 AM ET Company Participants Frederic Cren - CEO Jean Volatier - CFO Michael Cooreman - Chief Medical Officer Conference Call Participants Ed ...
2023-09-28 16:28:45 ET More on Inventiva Inventiva: An Untenable Cash Position Despite Enviable Data Inventiva and Hepalys Pharma to develop and commercialize Lanifibranor in Japan and South Korea Inventiva announced €35.7M funding, eyes future raise to meet o...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-06-30 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Arrival (ARVL) is expected to report for quarter end 2023-06-30 Treasure Global Inc. (TGL) is expected to report $-0.16 for Q4 2023 Manch...
2023-09-21 01:42:37 ET More on Inventiva Seeking Alpha’s Quant Rating on Inventiva Historical earnings data for Inventiva Financial information for Inventiva Inventiva: An Untenable Cash Position Despite Enviable Data Inventiva announced Ȋ...
2023-08-31 13:06:38 ET More on Inventiva Inventiva: An Untenable Cash Position Despite Enviable Data Inventiva jumps 25% after mid-stage data for NASH candidate Inventiva GAAP EPS of -€1.31 misses by €0.02, revenue of €12.18M misses by €0....
2023-08-14 13:19:20 ET Despite recent setbacks, drugmakers are still forging ahead in their quest to develop effective treatments for non-alcoholic steatohepatitis, or NASH, a growing public health concern that could represent a roughly $108B global market opportunity by 2030. According...
2023-07-16 09:01:42 ET Summary IVA has robust data from a mid-stage NASH trial. They have an ongoing pivotal study running, to topline in H2 2025. They don't have enough cash to complete that trial. Inventiva ( IVA ) is a small French company developing medicines...
News, Short Squeeze, Breakout and More Instantly...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-06-30 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Arrival (ARVL) is expected to report for quarter end 2023-06-30 Treasure Global Inc. (TGL) is expected to report $-0.16 for Q4 2023 Manch...